Literature DB >> 22576268

Is it a glioblastoma? In dubio pro 5-ALA!

Marcel A Kamp1, Antonio Santacroce, Samis Zella, Dorothea C Reichelt, Jörg Felsberg, Hans-Jakob Steiger, Jan Frederick Cornelius, Michael Sabel.   

Abstract

BACKGROUND: Differential diagnosis of unclear contrast-enhancing cerebral lesions includes cerebral metastases as well as malignant glioma. In the majority of cases, a definite preoperative diagnosis by neuroradiological assessment alone cannot be made. Since the introduction of 5-ALA-induced fluorescence-guided resection in the treatment of glioblastoma (GBM), the preoperative putative diagnosis of metastasis vs. GBM triggers a specific preoperative preparation of the patients. We analyzed the patient population with known cancer outside the central nervous system who underwent surgery for an assumed cerebral metastasis and for whom the intraoperative diagnosis was corrected to a malignant glioma.
METHODS: Retrospective analysis of patients with a known primary cancer who were operated on for an assumed cerebral metastasis, which turned out to be a GBM. The patients were treated at our center between January 2008 and June 2011.
RESULTS: We identified ten patients who underwent surgery for an assumed cerebral metastasis and for whom the diagnosis was corrected intraoperatively to a malignant glioma by frozen section. The median age was 68 years (41-82 years). The female-to-male ratio was 2:8. In all patients, the final histopathological analysis of the intracerbral tumors revealed a glioblastoma, while the patients suffered from diverse primary carcinomas.
CONCLUSION: A malignant glioma should always be considered as a differential diagnosis of an unclear contrast-enhancing cerebral lesion even for patients with a known malignancy. Furthermore, we make the case for a more liberal indication for 5-ALA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22576268     DOI: 10.1007/s00701-012-1369-2

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  7 in total

1.  5-ALA fluorescence behavior of cerebral infectious and inflammatory disease.

Authors:  Julia Steinmann; Marion Rapp; Bernd Turowski; Hans-Jakob Steiger; Jan Frederick Cornelius; Michael Sabel; Marcel A Kamp
Journal:  Neurosurg Rev       Date:  2017-06-07       Impact factor: 3.042

2.  Treatment of glioblastoma in elderly patients.

Authors:  Florian Stockhammer
Journal:  CNS Oncol       Date:  2014-03

3.  Quantification of PpIX-fluorescence of cerebral metastases: a pilot study.

Authors:  Johannes Knipps; Igor Fischer; Lisa M Neumann; Marion Rapp; Maxine Dibué-Adjei; Christiane Freiin von Saß; Jan-Malte Placke; Hendrik-Jan Mijderwijk; Hans-Jakob Steiger; Michael Sabel; Jan-Frederick Cornelius; Marcel A Kamp
Journal:  Clin Exp Metastasis       Date:  2019-08-02       Impact factor: 5.150

4.  The use of 5-aminolevulinic acid fluorescence guidance in resection of pediatric brain tumors.

Authors:  M Preuß; C Renner; W Krupp; H Christiansen; L Fischer; A Merkenschlager; W Kieß; W Müller; N Manzo; J Meixensberger; U Nestler
Journal:  Childs Nerv Syst       Date:  2013-05-25       Impact factor: 1.475

5.  The use of 5-aminolevulinic acid in resection of pediatric brain tumors: a critical review.

Authors:  Chenran Zhang; Frederick A Boop; John Ruge
Journal:  J Neurooncol       Date:  2018-11-15       Impact factor: 4.130

6.  Photosensitizer (PS)-cyanine dye (CD) conjugates: Impact of the linkers joining the PS and CD moieties and their orientation in tumor-uptake and photodynamic therapy (PDT).

Authors:  Nadine S James; Penny Joshi; Tymish Y Ohulchanskyy; Yihui Chen; Walter Tabaczynski; Farukh Durrani; Masayuki Shibata; Ravindra K Pandey
Journal:  Eur J Med Chem       Date:  2016-06-29       Impact factor: 6.514

7.  5-ALA fluorescence of cerebral metastases and its impact for the local-in-brain progression.

Authors:  Marcel A Kamp; Igor Fischer; Julia Bühner; Bernd Turowski; Jan Frederick Cornelius; Hans-Jakob Steiger; Marion Rapp; Philipp J Slotty; Michael Sabel
Journal:  Oncotarget       Date:  2016-10-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.